What’s the next “big thing” on the horizon that will significantly alter the pharma/biopharma market, your operations, or the way you do business?
We took part in a roundtable in Pharma’s Almanac where our Global Product Director, David Levy, discusses the ‘next big thing’ in the pharma industry. He mentions how a company’s digital transformation strategy can only truly succeed if a universal digital data connectivity solution is adopted.
Read the article in full here.
What do you think most differentiates the U.S. pharma/biopharma industry or the market?
Here, our Global Product Director, David Levy, discussed how the US pharma industry differs from others around the globe by focusing highly on R&D, albeit within the strictest regulatory framework. As well as how maturing technology, artificial intelligence (AI), computational power, and sequencing is now making inroads into pharma.
